{"id":933243,"date":"2026-02-02T08:48:32","date_gmt":"2026-02-02T13:48:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nexalin-highlights-its-expanding-body-of-peer-reviewed-neuroimaging-research-confirming-its-difs-technology-as-the-leader-in-evidenced-based-non-invasive-brain-stimulation\/"},"modified":"2026-02-02T08:48:32","modified_gmt":"2026-02-02T13:48:32","slug":"nexalin-highlights-its-expanding-body-of-peer-reviewed-neuroimaging-research-confirming-its-difs-technology-as-the-leader-in-evidenced-based-non-invasive-brain-stimulation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nexalin-highlights-its-expanding-body-of-peer-reviewed-neuroimaging-research-confirming-its-difs-technology-as-the-leader-in-evidenced-based-non-invasive-brain-stimulation\/","title":{"rendered":"Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS\u2122 Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation"},"content":{"rendered":"

\nPeer-Reviewed Imaging Across Multiple Indications Validates Nexalin\u2019s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation Techniques
\n<\/h2>\n
\n

HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL)<\/b> (the \u201cCompany\u201d or \u201cNexalin\u201d), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS\u2122) of the brain, today highlighted Nexalin\u2019s rigorous peer-reviewed clinical research validating its proprietary neurostimulation technology across multiple neurological and psychiatric conditions. Currently, Nexalin is advancing its \u201cmood-military-memory\u201d clinical business plan with the FDA by publishing and submitting extensive clinical data.<\/p>\n

Recent peer-reviewed and published data collectively span Insomnia and Depression (mood), traumatic brain injury and PTSD (military), Alzheimer\u2019s disease (memory), and, most recently, attention deficit hyperactivity disorder (ADHD). Together, this body of clinical evidence continues to support Nexalin\u2019s clinical business plan presented in recent pre-submission meetings with the FDA.<\/p>\n

Nexalin\u2019s growing body of published data consistently demonstrates objective normalization of abnormal brain activity and network function. This normalization of abnormal brain function is validated through traditional patient symptom surveys, advanced neuroimaging, and other bioelectrical biomarkers administered pre- and post-treatment.<\/p>\n

Unlike inferior proposed neurostimulation devices that rely on minimal localized, surface-level stimulation, Nexalin\u2019s clinical research has consistently incorporated objective bioelectrical brain imaging data using advanced modalities, including MRI, functional MRI (fMRI), magnetoencephalography (MEG), electroencephalography (EEG), and positron emission tomography (PET). These objective measures demonstrate engagement and regulation of deep disturbed brain networks associated with mental health disorders. The collective dataset also demonstrates Nexalin\u2019s ability to penetrate and treat networks deep in the brain, rather than relying on superficial or localized effects offered by other stimulators.<\/p>\n

\u201cAcross multiple independent studies, we are not just observing that patients feel better\u2014we are seeing measurable changes in how the brain functions,\u201d said Mark White, CEO of Nexalin Technology. \u201cThat distinction matters. Nexalin is a powerful whole-brain neurostimulation medical device that evidence indicates can penetrate deep in the brain to dramatically increase positive treatment response. Nexalin is not another battery-operated internet device sold to consumers. Our DIFS\u2122 technology is designed to regulate abnormal neural signaling and normalize disrupted brain networks, and we have objective imaging data to support that mechanism.\u201d<\/p>\n

Most recently, a randomized, double-blind, sham-controlled trial published in Molecular Psychiatry demonstrated that Nexalin\u2019s non-invasive DIFS\u2122 neurostimulation produced objective normalization of abnormal gamma-frequency brain activity measured with MEG and EEG. The study showed improved communication across brain networks associated with attention, cognitive control, mood, sleep, and social functioning\u2014directly linking clinical outcomes to measurable changes in brain activity.<\/p>\n

Earlier peer-reviewed publications have demonstrated similar network-level effects in other indications:<\/p>\n